Results of a study investigating CAR T therapy Lisocabtagene maraleucel in patients with diffuse large b-cell lymphoma not eligible for stem cell transplant.
Home / Resource Library / Liso-cel as a second-line treatment for patients with R/R LBCL not intended for HSCT